A Case Report of Pathologically Complete Response of a Huge Lymph Node Metastasis of Colorectal Cancer After Treatment with Intratumoral Oncolytic Virus H101 and Capecitabine.
Yaqin WangTianxiao WangYuewei ZhangPublished in: ImmunoTargets and therapy (2024)
Unresectable recurrent lymph node metastasis of colorectal cancer (CRC) is considered as an incurable disease clinically and has a very poor prognosis. Here, we report a male KRAS wild-type CRC case with a huge abdominal lymph node metastasis (12 cm in diameter) after CRC surgery. After three intratumoral injections of oncolytic virus (H101) combined with four cycles of low-dose oral capecitabine, the size of the metastatic lymph node shrank remarkably in response to the anticancer drug and a complete response (CR) was achieved with progression-free survival (PFS) of 19 months. The main adverse reaction was mild fever, which was relieved after physical cooling. The patient is in a general good condition now without any relapse of abdominal lymph node for over a year. On this basis, we propose that the combination therapy of oncolytic virus and capecitabine could be a promising clinical therapeutic strategy for unresectable recurrent lymph node metastasis in CRC patients.
Keyphrases
- lymph node metastasis
- locally advanced
- squamous cell carcinoma
- lymph node
- poor prognosis
- neoadjuvant chemotherapy
- free survival
- wild type
- combination therapy
- papillary thyroid
- low dose
- phase ii study
- end stage renal disease
- long non coding rna
- rectal cancer
- metastatic breast cancer
- chronic kidney disease
- ejection fraction
- metastatic colorectal cancer
- minimally invasive
- newly diagnosed
- radiation therapy
- sentinel lymph node
- physical activity
- peritoneal dialysis
- case report
- phase iii
- high dose
- atrial fibrillation
- coronary artery disease
- coronary artery bypass
- acute coronary syndrome
- percutaneous coronary intervention
- drug induced